BBM-C101

DRUG2 trials

Sponsors

Shanghai Mianyi Biopharmaceutical Co., Ltd., Tianjin First Central Hospital

Conditions

HPV16/18 PositiveHigh-grade Squamous Intraepithelial Lesions of the Cervix Associated With Human Papillomavirus (HPV) Type 16 and/or HPV Type 18 Infection

Phase 1

Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)

Not yet recruitingNCT07668960

Shanghai Mianyi Biopharmaceutical Co., Ltd.High-grade Squamous Intraepithelial Lesions of the Cervix Associated With Human Papillomavirus (HPV) Type 16 and/or HPV Type 18 Infection

Start: 2026-06-17End: 2029-12-30Target: 60Updated: 2026-06-25

Unknown Phase

Investigator-Initiated Study of BBM-C101 Injection in Subjects With HPV16/18 Infection

Not yet recruitingNCT07714577

Tianjin First Central HospitalHPV16/18 Positive

Start: 2026-07-30End: 2031-08-01Target: 200Updated: 2026-07-20